Editorial

Involvement of IGF Proteins in Severe Allergic Asthma: New Roles for Old Players

Participación de las proteínas IGF en el asma alérgica grave: nuevas funciones para viejos jugadores

Asthma is a chronic inflammatory disease characterised by reversible airflow obstruction, bronchial hyperresponsiveness (AHR), inflammation and airways remodelling (i.e., mucosal hypersecretion and goblet cell metaplasia, thickening of subepithelial basement membrane, airway smooth muscle hypertrophy/hyperplasia, angiogenesis).[1] Various clinical phenotypes have been described based on the innate inflammatory profile (e.g., eosinophilic, neutrophilic, paucigranulocytic, mixed granulocytic), remodelling and obstruction of the airways (from mild to severe), the reversibility of bronchoconstriction, the type of trigger (allergic/non-allergic), or the age of asthma onset (early or late asthma).[1] In view of this, search for the underlying pathophysiological mechanisms and the different asthma endotypes will facilitate future precision medicine for this heterogeneous disease by identifying new and more specific biomarkers and molecular targets.

Among the different molecules and pathways that can help to better understand moderate–severe allergic asthma, proteins of the IGF (Insulin-like Growth Factors) system play a relevant role. These components include the IGF1 and IGF2 ligands, the IGF receptors (IGF1R and IGF2R) and the IGF binding proteins (IGFBPs 1–6); in addition, IGFBPs interplay with other proteins (e.g., Insulin Like Growth Factor Binding Protein Acid Labile Subunit/IGFALS), specific proteases (e.g., pappalysins) and their inhibitors (e.g., stanniocalcins).[2] IGF signalling develops important roles in respiratory pathological scenarios, such as allergic asthma. Results in both murine models and patients show that IGF signalling impacts the asthmatic pathology at several levels: T2^{high} inflammation (e.g., IL-4, IL-5, IL-13), eosinophilia, mucus production, AHR, subepithelial fibrosis, smooth muscle hyperplasia, bronchial remodelling.[3] The ubiquitously expressed IGF1R tyrosine kinase receptor has been recently involved in all these disease signs and proposed as an interesting target in the treatment of allergic asthma.[4,5] On the other hand, IGF2 receptor (IGF-2R/cation-independent mannose-6-phosphate receptor), an alternative receptor for IGF2 that modulates IGF1R activity by targeting IGF2 to lysosomal degradation, also interacts at the cell surface with mannose-6-phosphate-containing ligands, such as latent TGF-β and CD26/dipeptidyl peptidase 4 (DPP4).[6,7] CD26 is a serine protease involved in asthma whose membrane levels are upregulated on bronchial epithelial cells in response to

IL-13.[8] In addition, shedding of CD26 generates a soluble version (sCD26) that promotes the TGF-β-induced epithelial-mesenchymal transition (EMT) in bronchial epithelial cells and contributes to airway remodelling.[9] Thus, several lines of evidence interconnect IGF signalling components, TGF-β, CD26 and asthma severity.

In an additional layer of complexity to control of IGF activity are IGFBPs, IGFALS, IGFBP-targeted pappalysin proteases and their inhibitors, stanniocalcins; most of them have been involved in asthma pathobiology.[2,10–13] IGFBP3 is a plasma protein that has been associated with the severity of asthma and bronchial remodelling as well as forms a high affinity ternary complex with IGFALS and IGFs.[2,3,10] These complexes retain IGFs in blood circulation, which inhibits their pro-inflammatory function by preventing the binding to IGF1R.[2,10] Post-translational modifications of IGF-BPs (e.g., phosphorylation, proteolysis) favour the release of "free" bioactive IGF from these complexes, especially cleavage of IGFBPs mediated by members of the pappalysin (PAPP) family: IGFBP-4 by PAPP-A and IGFBP-3/5 by PAPP-A2.[2,3] Indeed, levels of PAPP-A and IGFBP-4 (but not IGF-1) are significantly higher in severe allergic asthma and reduced upon treatment with Omalizumab.[11] On the other hand, anti-inflammatory effects of IGFBP3 could be independent of IGFs and be mediated by its own receptor TMEM219/IGFBP-3R,[10] which explains why inhaled formulations of IGFBP3 peptides tested in murine models of severe neutrophilic asthma (OVALPS OVA mice) lead to reduced inflammation, AHR, and pathological changes.[12]

The importance of IGFBPs in allergic asthma has been reinforced in a recent paper, where a nontargeted strategy (iTRAQ-LC-MS/MS) was used to compare the serum proteome of healthy donors and patients with either rhinitis or allergic/non-allergic asthma with different severities.[13] Significant differences were obtained in a good number of proteins, with IGFALS standing out for its association with a particular phenotype: moderate–severe allergic asthma.[13] IGFALS is an 66–85 kDa leucine rich repeat (LRR) glycoprotein present in various biofluids, vesicles (exosomes), and cell types (hepatocytes, epithelial cells, monocytes). The IGFALS gene encodes a protein with 20 LRRs, domains also present in numerous paralogue genes (e.g., LRRC32, Toll-like receptors; https://www.genecards.org/cgi-bin/carddisp.pl?gene=IGFALS#paralogs), some of them associated with asthma.[14,15] Elevation of IGFALS in

moderate–severe allergic asthma was further validated by ELISA in a small group of patients.[13] However, a potential translation to the clinical setting will require a much more extensive validation in different asthma phenotypes/endotypes and an exhaustive search for the biological functions of IGFALS, both ongoing processes. In conclusion, several lines of evidence and recent experimental data collected by multidisciplinary research groups seem to strengthen the role of the IGF proteins and related proteins as potential therapeutic targets in severe allergic asthma.

Conflicts of Interest

The authors have no conflicts of interest.

References

1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391:783–800.
2. Argente J, Chowen JA, Pérez-Jurado LA, Frystyk J, Oxvig C. One level up: abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology. EMBO Mol Med. 2017;9:1338–45.
3. Wang Z, Li W, Guo Q, Wang Y, Ma L, Zhang X. Insulin-like growth factor-1 signaling in lung development and inflammatory lung diseases. Biomed Res Int. 2018;2018:6057589.
4. Piñeiro-Hermida S, Alfaro-Arnedo E, Gregory JA, Torrens R, Ruíz-Martínez C, Adner M, et al. Characterization of the acute inflammatory profile and resolution of airway inflammation after Igf1r-gene targeting in a murine model of HDM-induced asthma. PLoS One. 2017;12:e0190159.
5. Piñeiro-Hermida S, Gregory JA, López IP, Torrens R, Ruíz-Martínez C, Adner M, et al. Attenuated airway hyperresponsiveness and mucus secretion in HDM-exposed Igf1r-deficient mice. Allergy. 2017;72:1317–26.
6. Brown J, Jones EY, Forbes BE. Interactions of IGF-II with the IGF2R/cation-independent mannose-6-phosphate receptor mechanism and biological outcomes. Vitam Horm. 2009;80:699–719.
7. Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol. 2001;167:6745–55.
8. Nieto-Fontarigo JJ, González-Barcala FJ, San José E, Arias P, Nogueira M, Salgado FJ. CD26 and asthma: a comprehensive review. Clin Rev Allergy Immunol. 2019;56:139–60.
9. Sun J, Chu S, Lu M, Pan Q, Li D, Zheng S, et al. The roles of dipeptidyl peptidase-4 and its inhibitors in the regulation of airway epithelial–mesenchymal transition. Exp Lung Res. 2020;46:163–73.
10. Lee H, Kim SR, Oh Y, Cho SH, Schleimer RP, Lee YC. Targeting insulin-like growth factor-I and insulin-like growth factor – binding protein-3 signaling pathways. A novel therapeutic approach for asthma. Am J Respir Cell Mol Biol. 2014;50:667–77.
11. Bulut I, Ozseker ZF, Coskun A, Serteser M, Unsal I. Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab. J Asthma. 2018;55:1116–21.
12. Kim SR, Lee YC, Park HJ, Park KH. An inhaled IGFBP-3 peptide attenuates steroid-resistant neutrophilic bronchial asthma through modulation of ER stress. Eur Resp J. 2019;54:OA4955.
13. Nieto-Fontarigo JJ, González-Barcala FJ, Andrade-Bulos LJ, San-José ME, Cruz MJ, Valdés-Cuadrado L, et al. iTRAQ-based proteomic analysis reveals potential serum biomarkers of allergic and nonallergic asthma. Allergy. 2020, http://dx.doi.org/10.1111/all.14406.
14. Meyer-Martin H, Hahn SA, Beckert H, Belz C, Heinz A, Jonuleit H, et al. GARP inhibits allergic airway inflammation in a humanized mouse model. Allergy. 2016;71:1274–83.
15. Reijmerink NE, Bottema RWB, Kerkhof M, Gerritsen J, Stelma FF, Thijs C, et al. TLR-related pathway analysis: novel gene–gene interactions in the development of asthma and atopy. Allergy. 2010;65:199–207.

Sara Vázquez-Mera [a], José G. Pichel [b], Francisco Javier Salgado [a,*]

[a] *Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain*
[b] *Lung Cancer and Respiratory Diseases Unit (CIBIR), Fundación Rioja Salud, Biomedical Research Networking Center on Respiratory Diseases (CIBERES, ISCIII), Spain*

[*] Corresponding author.
E-mail address: franciscojavier.salgado@usc.es (F.J. Salgado).